411 related articles for article (PubMed ID: 25670046)
1. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
Zhang Y; Wright C; Flores A
J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
5. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
Pitarokoili K; Hellwig K; Lukas C; Gold R
Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
[TBL] [Abstract][Full Text] [Related]
6. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
7. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
9. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
10. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
[TBL] [Abstract][Full Text] [Related]
11. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
12. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
Clerico M; Artusi CA; Di Liberto A; Rolla S; Bardina V; Barbero P; De Mercanti SF; Durelli L
Expert Opin Drug Saf; 2017 Aug; 16(8):963-972. PubMed ID: 28641055
[TBL] [Abstract][Full Text] [Related]
14. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
16. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
17. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
Schneider R; Bellenberg B; Hoepner R; Kolb EM; Ellrichmann G; Haghikia A; Gold R; Lukas C
PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
[TBL] [Abstract][Full Text] [Related]
19. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
20. Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis?
AlTahan AM; Berger T; AlOrainy IA; AlTahan H
Am J Case Rep; 2019 Jan; 20():101-105. PubMed ID: 30674865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]